These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 32654098)

  • 1. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
    J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
    Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R
    Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
    Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
    J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
    Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
    Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
    Asensio E; Acunzo R; Uribe W; Saad EB; Sáenz LC
    J Interv Card Electrophysiol; 2020 Nov; 59(2):315-320. PubMed ID: 32418181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
    JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
    Danjuma MI; Sinha U; Fatima H; Mohamed MFH; Nathoe H
    Eur J Clin Invest; 2020 Nov; 50(11):e13407. PubMed ID: 32918829
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.
    Samuel S; Friedman RA; Sharma C; Ganigara M; Mitchell E; Schleien C; Blaufox AD
    Heart Rhythm; 2020 Nov; 17(11):1960-1966. PubMed ID: 32621881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.
    Tuncer T; Karaci M; Boga A; Durmaz H; Guven S
    Cardiol Young; 2020 Oct; 30(10):1482-1485. PubMed ID: 32686633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
    Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
    Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
    Monzani A; Genoni G; Scopinaro A; Pistis G; Kozel D; Secco GG
    Eur J Clin Invest; 2020 Jun; 50(6):e13258. PubMed ID: 32356580
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic.
    Rubin GA; Desai AD; Chai Z; Wang A; Chen Q; Wang AS; Kemal C; Baksh H; Biviano A; Dizon JM; Yarmohammadi H; Ehlert F; Saluja D; Rubin DA; Morrow JP; Avula UMR; Berman JP; Kushnir A; Abrams MP; Hennessey JA; Elias P; Poterucha TJ; Uriel N; Kubin CJ; LaSota E; Zucker J; Sobieszczyk ME; Schwartz A; Garan H; Waase MP; Wan EY
    JAMA Netw Open; 2021 Apr; 4(4):e216842. PubMed ID: 33890991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
    Gunay S; Caliskan S; Sigirli D; Sahin E
    Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
    Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
    Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.